The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in ...

In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

A group of vaccine-skeptical doctors and mandate opponents is challenging the CDC’s childhood immunization schedule in ...

Wegovy is now positioned as the first and only GLP-1 treatment.

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

In a groundbreaking development, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver ...

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...